Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Spectral Medical Inc EDTXF


Primary Symbol: T.EDT

Spectral develops devices for unmet medical needs. Sepsis occurs in 1.7M Americans/year causing 250K deaths, often caused by endotoxin. Our devices measure and remove endotoxin from the bloodstream. An FDA confirmatory trial is underway. Dialco, a Spectral sub, offers SAMI, a novel instrument for renal replacement, cleared by FDA. Dialco is seeking FDA approval for DIMI a unique home dialysis enabler. These devices have large commercial potential


TSX:EDT - Post by User

Comment by palinc2000on Feb 26, 2024 5:56pm
94 Views
Post# 35900227

RE:RE:RE:RE:RE:RE:RE:RE:Wonder what edt’s FORTUNE COOKIE

RE:RE:RE:RE:RE:RE:RE:RE:Wonder what edt’s FORTUNE COOKIE

Where did you see that Baxter will be getting "" half" of the revenues?

BlueJays9293 wrote: Sometimes it's crazy to me what people waste their time thinking/talking about.  I've seen Spectral switch between CAD and USD all within the same Sedar filing.  Talk about missing the forest for the trees.  Then lately I see all this complaing about the size of the distribution agreement milestone payments.  Well to these people I ask, how many tens of millions do you think Baxter is going to have to spend in marketing and commercialization in year #1 & #2 of PMX authorization????  50mm?  75mm?  100mm?  Even with FDA approval it costs a ton of money getting the word out, convincing doctors/hospitals/insurance companies and ultimately driving PMX to become the SOC as quickly as possible.

Go look at Spectral's slide # 16 again and you will see that after Baxter pays these expenses, their half of PMX revenue won't even cover these cost at a 15% penetration.  Spectral has Zero cost/expenses commercializing PMX, that huge burden is completely on Baxter.  Our revenue/earnings off of PMX is a pure as possible.  

 

<< Previous
Bullboard Posts
Next >>